Chemokines such as CXCL9 and CXCL10 can orchestrate the migration of effector CXCR3+ immune cells such as Th1 cells into the tumor sites, subsequently shaping both the tumor immunity and therapeutic responses [23,24,25,26]. This evidence concerns the gene CXCR3 and neoplasm.